Sign in Subscribe
Genetic research

Breakthrough in Cancer Gene Therapy: Researchers Develop New Synthetic Nanocarrier for Targeted Therapy

Strategic Insights

— 1 min read

A team of researchers from Northwestern University has made a significant breakthrough in the field of cancer gene therapy. They have developed a new synthetic nanocarrier, PPDP2, which can block the RAS signaling system, a key driver of pancreatic cancer. This nanocarrier, composed of poly(ethylene glycol)--poly(propylene sulfide) (PEG-PPS), is capable of delivering mRNA to pancreatic tumor cells, interrupting the RAS signaling system and reducing tumor growth. The research, published in ACS Applied Bio Materials, has been peer-reviewed and demonstrates the potential of this new technology for targeted therapy.

Key Takeaways:

  • The researchers developed a new synthetic nanocarrier, PPDP2, which can block the RAS signaling system, a key driver of pancreatic cancer.
  • The nanocarrier is composed of poly(ethylene glycol)--poly(propylene sulfide) (PEG-PPS) and is capable of delivering mRNA to pancreatic tumor cells.
  • The delivered mRNA results in the expression of RAS degrader protein, RRSP, which degrades RAS and reduces cell proliferation.
  • Pancreatic tumors are reduced and residual tumors lack detectable RAS and phosphorylated ERK.
  • The research demonstrates the potential of this new technology for targeted therapy in pancreatic cancer.
  • The study's lead author is Simseok A. Yuk, a researcher from Northwestern University's Department of Biomedical Engineering.

Statistics:

  • The study demonstrates a 50% reduction in pancreatic tumor growth using the PPDP2 nanocarrier.
  • The nanocarrier is capable of delivering mRNA to pancreatic tumor cells with high specificity, targeting all RAS isoforms.
  • The study shows that the noncatalytic RAS-binding domain of RRSP provides high specificity for RAS, reducing off-target effects.
  • The research suggests that this technology can be used to develop targeted therapies for other RAS-driven cancers.

Sources:

  • "Expression of a RAS Degrader via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors." ACS Applied Bio Materials, 2025.
  • Northwestern University. "Researchers Develop New Synthetic Nanocarrier for Targeted Therapy in Pancreatic Cancer." [No date].

Read more